Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19
- 21 November 2020
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 65 (7-8), 27-30
- https://doi.org/10.37489/0235-2990-2020-65-7-8-27-30
Abstract
The article evaluates the results of Riamilovir use in treatment of patients with a moderate form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the average time required to complete resolution of symptoms during treatment with the drug was 6-7 days. The first negative result of PCR analysis for the SARS-CoV-2 virus was registered on the 10-11th day of therapy; two consecutive negative PCR results for the SARS-CoV-2 virus were registered in the majority of patients by day 14–19 of treatment in 63±4.28%. The body temperature of the majority of patients (75%) returned to normal by the 4th day of treatment. CT scan showed improvement in the lungs of patients: a repeated CT scan performed on average on day 19 from the start of therapy showed no lung damage or no progression in 10±3.0% of patients following therapy. The CT scan of the lungs performed in 1-2 months after the treatment showed that the number of patients with no lung damage increased to 27±4.44%. As a result of treatment, a decrease in the C-reactive protein index was observed in patients. The tolerability level of the drug was assessed as good: no adverse events or significant deviations in laboratory parameters were detected.Keywords
This publication has 9 references indexed in Scilit:
- Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19Annals of Internal Medicine, 2020
- Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled TrialClinical Infectious Diseases, 2020
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialBMJ, 2020
- Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled TrialMed, 2020
- History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae)Russian Journal of Infection and Immunity, 2020
- nucleoside analogues for the treatment of influenza: history and experienceJournal Infectology, 2019
- Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infectionsKazan medical journal, 2018
- A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenzaInfekcionnye bolezni, 2017
- Identification of new human coronavirusesExpert Review of Anti-infective Therapy, 2007